Literature DB >> 34185297

Pancreatic Tumor Microenvironment.

Kai Wang1, Hong He2.   

Abstract

The pancreatic ductal adenocarcinoma (PDAC) microenvironment is a diverse and complex milieu of immune, stromal, and tumor cells and is characterized by a dense stroma, which mediates the interaction between the tumor and the immune system within the tumor microenvironment (TME). The interaction between stromal and tumor cells signals and shapes the immune infiltration of TME. The desmoplastic compartment contains infiltrated immune cells including tumor-associated macrophages (TAMs) and large numbers of fibroblasts/myofibroblasts dominated by pancreatic stellate cells (PSCs) which contribute to fibrosis. The highly fibrotic stroma with its extensive infiltration of immunosuppressive cells forms the major component of the pro-tumorigenic microenvironment (Laklai et al. Nat Med 22:497-505, 2016, Zhu et al. Cancer Res 74:5057-5069, 2014) provides a barrier to the delivery of cytotoxic agents and limits T-cell access to tumor cells (Feig et al. Proc Natl Acad Sci USA 110:20212-20217, 2013, Provenzano et al Cancer Cell 21:418-429, 2012). Activated PSCs reduced infiltration of cytotoxic T cells to the juxtatumoral stroma (immediately adjacent to the tumor epithelial cells) of PDAC (Ene-Obong et al. Gastroenterology 145:1121-1132, 2013). M1 macrophages activate an immune response against tumor, but M2 macrophages are involved in immunosuppression promoting tumor progression (Noy and Pollard Immunity 41:49-61, 2014, Ruffell et al. Trends Immunol 33:119-126, 2012). The desmoplastic stroma is reported to protect tumor cells against chemotherapies, promoting their proliferation and migration. However, experimental depletion of the desmoplastic stroma has led to more aggressive cancers in animal studies (Nielsen et al. World J Gastroenterol 22:2678-2700, 2016). Hence reprogramming rather than simple depletion of the PDAC stroma has the potential for developing new therapeutic strategies for PC treatment. Modulation of PSCs/fibrosis and immune infiltration/inflammation composes the major aspects of TME reprogramming.

Entities:  

Keywords:  Alpha-smooth muscle actin (α-SMA); Collagens; Cytotoxic T cells; Extracellular matrix (ECM); Gemcitabine; Hypoxia; Hypoxia-inducible factors (HIFs); Immune checkpoint proteins; Myeloid-derived suppressor cells (MDSCs); Pancreatic ductal adenocarcinoma (PDAC); Pancreatic stellate cells (PSCs); Tumor immune response; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment (TME); Tumor-associated macrophages (TAMs)

Mesh:

Year:  2020        PMID: 34185297     DOI: 10.1007/978-3-030-59038-3_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  118 in total

Review 1.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

Review 2.  Stromal biology and therapy in pancreatic cancer: a changing paradigm.

Authors:  Albrecht Neesse; Hana Algül; David A Tuveson; Thomas M Gress
Journal:  Gut       Date:  2015-05-20       Impact factor: 23.059

3.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

4.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

5.  The stromal theca cell and postmenopausal endometrial adenocarcinoma.

Authors:  R Fienberg
Journal:  Cancer       Date:  1969-07       Impact factor: 6.860

Review 6.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 7.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

8.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Authors:  Hanane Laklai; Yekaterina A Miroshnikova; Michael W Pickup; Eric A Collisson; Grace E Kim; Alex S Barrett; Ryan C Hill; Johnathon N Lakins; David D Schlaepfer; Janna K Mouw; Valerie S LeBleu; Nilotpal Roy; Sergey V Novitskiy; Julia S Johansen; Valeria Poli; Raghu Kalluri; Christine A Iacobuzio-Donahue; Laura D Wood; Matthias Hebrok; Kirk Hansen; Harold L Moses; Valerie M Weaver
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

9.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Christine Feig; James O Jones; Matthew Kraman; Richard J B Wells; Andrew Deonarine; Derek S Chan; Claire M Connell; Edward W Roberts; Qi Zhao; Otavia L Caballero; Sarah A Teichmann; Tobias Janowitz; Duncan I Jodrell; David A Tuveson; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

10.  Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.

Authors:  Abasi Ene-Obong; Andrew J Clear; Jennifer Watt; Jun Wang; Rewas Fatah; John C Riches; John F Marshall; Joanne Chin-Aleong; Claude Chelala; John G Gribben; Alan G Ramsay; Hemant M Kocher
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.